Mice and other laboratory hosts vaccinated with radiationattenuated cercariae of Schistosoma mansoni develop high levels of protective immunity against subsequent challenge infection (14, 18) . The effector mechanism of vaccineinduced resistance in this irradiated cercariae model has been extensively analyzed with the aim of developing immunization methods using nonliving parasite antigens (5) . The results of these studies indicate that the immunity stimulated by the attenuated vaccine is both B and T lymphocyte dependent (13, 16) and most probably involves a cellmediated response requiring the participation of lymphokine (LK)-activated macrophages as effector cells. The latter hypothesis is based on the identification of an inbred mouse strain, P/N-J (P), which fails to develop vaccine-induced immunity and possesses unique defects in macrophage activation (1, 12) . That the P-mouse defects in vaccine-induced resistance and cell-mediated immune response are causally related is suggested by the close association observed between the two recessively inherited traits in the progeny of genetic crosses with highly resistant C57BL/6J (B6) mice (9) . These experiments have also indicated that the resistance defect of vaccinated P mice is controlled by a single major locus, rsm-J, which is unlinked to either the murine major histocompatibility complex or immunoglobulin heavy-chain loci (3) .
Mice of the inbred A/J (A) strain have also been shown to be deficient in their ability to develop irradiated vaccineinduced immunity, as well as in the generation of activated macrophages capable of killing schistosomula in vitro (8, 12) . To determine whether the A-and P-mouse defects in protective immunity and macrophage response are controlled by separate genetic loci, the inheritance of the traits was examined in (P x A)F1 crosses. by prior exposure to 50 kR of gamma radiation from a 'Co source (14) . Four weeks later, the immunized animals, along with age-matched control mice, were challenged by percutaneous infection of the abdominal skin (19) with approximately 150 unattenuated cercariae each. After 6 weeks, the recovery of adult worms developing from the challenge infection was measured by perfusion of the hepatic portal system (19) . The percent reduction in worm burden induced by vaccination (percent immunity) was then calculated by the equation [(c -v3)I] x 100, where c and v3 are the mean adult worm counts in the control and vaccinated animal groups, respectively. Differences in mean parasite recoveries between different groups were evaluated by Student's t test.
Vaccine-induced macrophage activation was assessed by measuring the larvicidal activity of schistosome-antigenelicited macrophages (6, 7) . Peritoneal cells were collected from mice vaccinated 4 weeks previously or unimmunized controls 16 to 20 h after intraperitoneal injection with 250 ,ug of soluble adult-worm antigen in phosphate-buffered saline and counted as previously described (6, 7) . Plastic-adherent monolayers were prepared by adding 8 x 105 macrophages to 16-mm culture wells (Costar, Cambridge, Mass.) in Dulbecco modified Eagle medium (GIBCO Laboratories, Grand Island, N.Y.) containing 10% fetal bovine sera (Hyclone, Logan, Utah), 2 mM L-glutamine, and 50 ,ug of gentamicin per ml. Nonadherent cells were removed by washing after 2 h of incubation. Target schistosomula prepared from cercariae by mechanical transformation and opsonized by incubation in chronic immune sera (6, 7) were then added at 80 per well. After 48 h of incubation at 37°C, macrophage-mediated larval killing was evaluated microscopically by the criteria of internal granularity and loss of internal structure and motility (6, 7) . Larvicidal activity is expressed as the mean percent dead schistosomula in duplicate cultures.
As previously described (3, 12) , vaccinated P mice develop low and often insignificant levels of immunity against challenge infection. In contrast, vaccinated B6 mice and the F1 hybrids of P and B6 animals developed high levels of resistance ( Table 1 ), indicating that the P-mouse immunity defect is inherited in a fully recessive manner. Similarly, as previously reported (3, 8) , inbred A-strain mice are also deficient in their capacity to develop vaccine-induced immunity, although they display levels of resistance somewhat higher than those of the fully defective P strain. As indicated by the results of F1 crosses with B6 mice, the A-strain defect in vaccine-induced immunity is also inherited as a fully recessive trait (Table 1) .
To test for complementation of the P-and A-strain defects, (P x A)F1 hybrids were vaccinated and tested for their immunity to challenge infection. In both of the experiments performed, the F1 mice displayed levels of vaccine-induced resistance which were significantly (P < 0.02) higher than those of either of the parental strains and statistically indistinguishable from those developed by the nondefective B6 strain (Table 1) . Thus, the results clearly demonstrate genetic complementation between the P-and A-strain defects in protective immunity.
As reported previously (1, 7, 8), vaccinated P-and Astrain mice have defects in macrophage activation in vivo, as evidenced by decreased larvicidal (as well as tumoricidal) activity of peritoneal macrophages elicited with specific parasite antigens. These deficiencies in macrophage response behave as recessive traits in P x B6 or A x B6 crosses (Table 2 ). To determine whether the P-and A-strain defects in macrophage activation are similar to the defects in resistance in being controlled by noncomplementing genetic loci, macrophages were elicited from vaccinated P, A, and (P x A)F1 mice at a time (4 weeks) corresponding to that of the cercarial challenge and tested for their capacity to kill schistosomula in vitro. The cells from the vaccinated P-and A-strain mice displayed low levels of larval killing which were not significantly different from that displayed by control macrophages elicited from nonvaccinated mice ( Table  2 ). In contrast, the macrophages from the immunized F1 mice displayed highly significant levels of schistosomulum killing comparable to that exhibited by cells from vaccinated nondefective B6 animals. These results confirm that the macrophage activation defects of immunized P-and A-strain mice are controlled by complementing genetic loci.
The data presented above formally establish that genetically distinct loci determine the impaired vaccine-induced resistance of P-and A-strain mice. At present the identity and chromosomal linkage of the genes controlling these defects are unclear. Interestingly, neither defect appears to be associated with the murine major histocompatibility complex (3; P. Brindley, R. Correa-Oliveira, S. James, D. McCall, and A. Sher, manuscript in preparation), even though a quantitative influence of the major histocompatibility complex on vaccine-induced immunity was noted in a previous study of H-2 congenic strains (15) .
The defects in vaccine-induced immunity of the P and A mouse strains appear to closely correlate with deficiencies in cell-mediated immune response and, in particular, with those relating to macrophage activation. For P mice, the defect in macrophage larvicidal activity appears to result from a deficiency in the capacity of T lymphocytes from these animals to produce gamma interferon when exposed to schistosome antigens and in the reduced ability of P-strain macrophages to respond to stimulation with this LK (1, 7) . That this combined macrophage activation deficiency may be responsible for the highly reduced vaccine-induced im- (9) . In addition, all other cellular or humoral immune responses examined in vaccinated P mice appear to be normal (11) or are genetically dissociable from the resistance defect (3) .
For the larvicidal defect displayed by vaccinated A mice, previous studies of macrophage activation for tumor cell killing (1, 2) indicated that it likely results solely from a deficiency in macrophage response to non-LK-activating stimuli rather than from decreased LK production and suggested therefore that the cellular defects of P-and Astrain mice might be functionally unrelated. In the present study, in the schistosome model (Table 2 ), the P-and A-strain defects in vaccine-induced macrophage activation complemented each other in the F1 generation, confirming that they are indeed genetically distinct and therefore under separate control. More interestingly for the analysis of schistosome immunity, the cocomplementation of the P-and A-strain macrophage activation and resistance defects provides yet another example of the close functional association of these two responses induced by vaccination with attenuated cercariae and further supports a causal relationship. The practical significance of this association has been demonstrated by the recent development of a nonliving experimental vaccine against murine S. mansoni infection based on parasite-antigen-induced macrophage activation and, as expected, influenced by genetic defects in this critical immune response (4, 10, 17) .
